Industries > Pharma > Global Anti-obesity Drugs Market Forecast 2020-2030

Global Anti-obesity Drugs Market Forecast 2020-2030

Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

PUBLISHED: 27 February 2020
PAGES: 285
PRODUCT CODE: PHA0720
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0720 Categories: , Tags: ,

covid-19

The global anti-obesity drugs market is estimated to have reached $1.9bn in 2019 and is expected to grow at a CAGR of 32% in the first half of the forecast period. In 2019, the innovator drugs submarket held 75% of the global anti-obesity drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 285-page report you will receive 146 tables and 137 figures– all unavailable elsewhere.

The 285-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Anti-obesity Drugs Market forecast from 2020-2030

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action:
• Incretion mimetics/GLP-1 agonists
• SNDRIs
• Lipase Inhibitors
• Serotonin receptor agonists
• Sympathomimetic-GABA receptor agonists
• Sympathomimetics

• Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Duration of Therapy:
• Long-term Drugs
• Short-term Drugs

• Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Innovator vs Generic Drugs:
• Innovator
• Generic Drugs

• Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Prescription vs OTC:
• Prescription Drugs
• OTC

• This report discusses and provides revenue forecasts from 2020-2030 for selected anti-obesity drugs:
• Saxenda
• Contrave/Mysimba
• Belviq
• Qysmia
• Xenical
• Alli

• This report provides individual revenue forecasts from 2020-2030 for these regional and national markets:
• US
• Japan
• EU5: Germany, France, Spain, Italy, UK
• BRIC: Brazil, Russia, China, India
• RoW

Global Anti-obesity Drugs Market Forecast 2020-2030

Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs.

• Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market:
• Arena Pharmaceuticals
• AstraZeneca
• Carmot Therapeutics
• CohBar
• Currax Pharmaceuticals LLC
• Eisai
• ERX Pharmaceuticals
• Gelesis
• GlaxoSmithKline (GSK)
• Hanmi Pharmaceutical
• LNC Therapeutics
• Novartis
• Novo Nordisk
• Pfizer
• Rhythm Pharmaceuticals, Inc.
• Roche
• Saniona
• Scohia Pharma, Inc.
• Sinil Pharmaceutical Co., Ltd
• Takeda
• Teva
• Vivus

• This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.

• This report gives an overview of pricing and reimbursement in the US and EU.

• This report provides a SWOT Analysis of the global anti-obesity drugs market.

• Key questions answered by this report:
• How is the anti-obesity drugs market evolving?
• What is driving and restraining anti-obesity drugs dynamics?
• How will each anti-obesity drugs submarket market grow over the forecast period and how much Sales will these submarkets account for in 2030?
• How will market shares of each anti-obesity drugs submarket develop from 2020-2030? Which individual technologies will prevail and how will these shifts be responded to?
• Which anti-obesity drugs submarket will be the main driver of the overall market from 2020-2030?
• How will political and regulatory factors influence regional anti-obesity drugs markets and submarkets?
• Will leading national anti-obesity drugs markets broadly follow macroeconomic dynamics, or will individual country sectors outperform the rest of the economy?
• How will market shares of the national markets change by 2030 and which nation will lead the market in 2030?
• Who are the leading players and what are their prospects over the forecast period?
• How will the sector evolve as alliances form during the period between 2020 and 2030?

Visiongain’s study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.

Buy our report today Global Anti-obesity Drugs Market Forecast 2020-2030: Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Anti-obesity Drugs Market Forecast 2020-2030


Download sample pages

Complete the form below to download your free sample pages for Global Anti-obesity Drugs Market Forecast 2020-2030


Latest Pharma news

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

READ

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

READ

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

READ

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

READ

Categories

Category